News and Press

ProteinLogic Attends JP Morgan 2020

CAMBRIDGE, UK (2020-01-17) – ProteinLogic, the biomarker discovery and exploitation company, has attended the JP Morgan Health week in San Francisco. CEO Nicolas Huber, who represented the company, attended a number of industry events to promote the innovative diagnostic technology of the company. He held meetings with a number of potential commercial partners, who showed…

Read More

ProteinLogic featured in GenomeWeb’s 360Dx Innovative test is considered of significance in the fight against TB

CAMBRIDGE, UK (2019-12-23) – ProteinLogic, the biomarker discovery and exploitation company, has been featured in GenomeWeb’s 360Dx diagnostics online, one of the leading diagnostics newsletters. The article followed interviews with ProteinLogic’s CEO, Dr Nicolas Huber, and a clinical collaborator of the company representing ProteinLogic’s study consortium, Dr Marcelo Cordeiro-Santos, as well as other experts in the field of TB…

Read More

ProteinLogic to present at BioSeed2020 Company selected by UKRI to be part of only 60 presenting companies

CAMBRIDGE, UK (2019-12-17) – ProteinLogic, the biomarker discovery and exploitation company, has been selected by UKRI to present at the prestigious BioSeed event. BioSeed is an early-stage life-sciences investment event, which provides a platform for only 60 innovative early-stage Life Sciences companies to present to over 100 specialist investors. The pitching session is followed by extensive one-to-one partnering as well as networking…

Read More

ProteinLogic selected to represent the UK in mission to China Company to participate in UKRI Global Business Innovation Programme in precision medicine

CAMBRIDGE, UK (2019-11-29) – ProteinLogic, the biomarker discovery and exploitation company, has been selected to represent the UK on the UKRI Global Business Innovation Programme (GBIP) in precision medicine on a mission to China. The GBIP is geared exclusively for Precision Medicine businesses working with technologies that enable early and accurate diagnosis to inform patient treatment,…

Read More

ProteinLogic to present at the 50th Union World Conference, Hyderabad, India

CAMBRIDGE, UK (2019-10-21) – ProteinLogic, the biomarker discovery and exploitation company, will be presenting results of its novel ImmiPrint®-TB test at the 50th Union World Conference on Lung Health, to be held in Hyderabad, India. Our prominent clinical collaborators will be presenting their findings on the use of  ImmiPrint®-TB as an active TB disease rule-out test…

Read More

ProteinLogic Attends the 71st AACC Meeting

CAMBRIDGE, UK (2019-08-06) – ProteinLogic, the biomarker discovery and exploitation company, is attending the 71st annual scientific meeting & clinical lab Expo of the American Association of Clinical Chemistry (AACC).   Dr Nicolas Huber, CEO of ProteinLogic, commented: “The AACC meeting, with its exclusive focus on laboratory diagnostics, is the most prestigious meeting to be attending…

Read More

ProteinLogic Completes Multi-Site Clinical Study on TB, Reports Results Exceeding WHO Requirements

CAMBRIDGE, UK (2019-08-01) – ProteinLogic, the biomarker discovery and exploitation company, today announces the completion of its multi-site study on the use of its novel diagnostic technology, ImmiPrint®, for the ruling-out of Active Tuberculosis (TB) disease from a blood sample. Previously, the company had shown that its ImmiPrint  technology could achieve the requisite clinical accuracy in…

Read More

ProteinLogic Appoints Dr Adrian Woolfson as Non-Executive Director

CAMBRIDGE, UK (2019-06-01) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Adrian Woolfson as Non-Executive Director. Dr Woolfson is the founder of ProteinLogic, having discovered soluble Cluster of Differentiation antigens that underpin ProteinLogic’s platform technology. He is currently serving as Executive Vice President of Research & Development, Sangamo Inc., CA, USA. Dr….

Read More

ProteinLogic Appoints Dr Edward Gibson as Non-Executive Director

CAMBRIDGE, UK (2018-09-01) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Edward Gibson as Non-Executive Director. Dr Gibson holds a holds a degree in Chemistry from Bristol University, and a PhD in Biochemistry from Oxford University, where he also performed postdoctoral research. Since then, he has held a number of senior leadership…

Read More